Clinical Trial Update: Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics [Phase 2]

View source ↗

Summary

Updates on a Phase 2 clinical trial exploring hyperpolarized Xenon-129 MRI as a multi-dimensional biomarker to assess pulmonary responses to COPD therapies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: University of Virginia | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING